Tom 6, Nr 2 (2020)
Prace oryginalne
Opublikowany online: 2020-07-09
Pobierz cytowanie

Efficacy and safety of 0.1% Tacrolimus ointment versus 0.05% Clobetasone butyrate ointment in childhood atopic dermatitis

Sanjoy Prasad Das, Mohammad Rafiqul Mowla, Deva Pratim Barua, Selim Mohammed Jahangir, Ismail Khan
DOI: 10.5603/FD.a2020.0003
·
Forum Dermatologicum 2020;6(2):33-39.

dostęp płatny

Tom 6, Nr 2 (2020)
Prace oryginalne
Opublikowany online: 2020-07-09

Streszczenie

Introduction: Atopic Dermatitis (AD) is a chronic relapsing skin condition characterized by intense itching, dry skin, redness, inflammation and exudation with significant morbidity. It often requires long-term use of topical corticosteroids but, patients’ adherence to corticosteroids may be limited by perceived risks and systemic adverse effects. Therefore, steroid-sparing topical agent is needed. To compare the efficacy and safety of 0.1% tacrolimus ointment and 0.05% clobetasone butyrate ointment in patients with childhood AD.  Materials and methods: This monocentric prospective open-label comparative study was carried out in the Department of Dermatology and Venereology, Chittagong Medical College Hospital. Two hundred patients of 2–10 years of age with mild to moderate AD involving ≤ 50% of the total body surface area (BSA) were randomly assigned. The treatment duration was 4 weeks and was followed-up for 12 weeks. The eczema area and severity index (EASI) and the physician’s global evaluation of clinical response were assessed and evaluated.  Results: Effective sample size was 176 as because 24 patients were dropped out during follow up. EASI score was significantly changed from baseline in follow up weeks and there was a statistically significant difference in the reduction of EASI of patients in Tacrolimus groups at the end of 2nd week, 4th week, 6th week than the other group (p < 0.05). At the end of 4 weeks treatment, a median improvement of ≥ 75% in EASI was observed in 86% and 57% of patients in Tacrolimus and Clobetasone Group, respectively. At the end of the 12 week follow-up period, these improvements persist. Both the regimens were well tolerated.  Conclusions: The overall therapeutic effectiveness was in favour of topical Tacrolimus ointment (0.1%) over topical Clobetasone butyrate ointment (0.05%) for the treatment of AD in children. 

Streszczenie

Introduction: Atopic Dermatitis (AD) is a chronic relapsing skin condition characterized by intense itching, dry skin, redness, inflammation and exudation with significant morbidity. It often requires long-term use of topical corticosteroids but, patients’ adherence to corticosteroids may be limited by perceived risks and systemic adverse effects. Therefore, steroid-sparing topical agent is needed. To compare the efficacy and safety of 0.1% tacrolimus ointment and 0.05% clobetasone butyrate ointment in patients with childhood AD.  Materials and methods: This monocentric prospective open-label comparative study was carried out in the Department of Dermatology and Venereology, Chittagong Medical College Hospital. Two hundred patients of 2–10 years of age with mild to moderate AD involving ≤ 50% of the total body surface area (BSA) were randomly assigned. The treatment duration was 4 weeks and was followed-up for 12 weeks. The eczema area and severity index (EASI) and the physician’s global evaluation of clinical response were assessed and evaluated.  Results: Effective sample size was 176 as because 24 patients were dropped out during follow up. EASI score was significantly changed from baseline in follow up weeks and there was a statistically significant difference in the reduction of EASI of patients in Tacrolimus groups at the end of 2nd week, 4th week, 6th week than the other group (p < 0.05). At the end of 4 weeks treatment, a median improvement of ≥ 75% in EASI was observed in 86% and 57% of patients in Tacrolimus and Clobetasone Group, respectively. At the end of the 12 week follow-up period, these improvements persist. Both the regimens were well tolerated.  Conclusions: The overall therapeutic effectiveness was in favour of topical Tacrolimus ointment (0.1%) over topical Clobetasone butyrate ointment (0.05%) for the treatment of AD in children. 
Pobierz cytowanie

Słowa kluczowe

atopic dermatitis; ointment; tacrolimus; clobetasone butyrate

Informacje o artykule
Tytuł

Efficacy and safety of 0.1% Tacrolimus ointment versus 0.05% Clobetasone butyrate ointment in childhood atopic dermatitis

Czasopismo

Forum Dermatologicum

Numer

Tom 6, Nr 2 (2020)

Strony

33-39

Data publikacji on-line

2020-07-09

DOI

10.5603/FD.a2020.0003

Rekord bibliograficzny

Forum Dermatologicum 2020;6(2):33-39.

Słowa kluczowe

atopic dermatitis
ointment
tacrolimus
clobetasone butyrate

Autorzy

Sanjoy Prasad Das
Mohammad Rafiqul Mowla
Deva Pratim Barua
Selim Mohammed Jahangir
Ismail Khan

Referencje (21)
  1. Patrizi A, Pileri A, Bellini F, et al. Atopic Dermatitis and the Atopic March: What Is New? Journal of Allergy. 2011; 2011: 1–5.
  2. Eczema (dermatitis). Common Skin Diseases 18th edition. 2013: 114–137.
  3. Hebert A. 2010 (July/August). Mild to Moderate Atopic dermatitis: A guide to therapeutic selection, Practical Dermatology for paediatrics. : 37.
  4. Dhar S. Atopic Dermatitis. Textbook of Pediatric Dermatology. 2014: 112–112.
  5. Systematic review of treatments for atopic eczema. Health Technology Assessment. 2000; 4(37).
  6. Tacrolimus Ointment. 2004.
  7. Morley N, Fry L, Walker S. Clinical evaluation of clobetasone butyrate in the treatment of children with atopic eczema, and its effect on plasma corticosteroid levels. Current Medical Research and Opinion. 2008; 4(3): 223–228.
  8. Williams HC, Pembroke AC, Forsdyke H, et al. London-born black caribbean children are at increased risk of atopic dermatitis. Journal of the American Academy of Dermatology. 1995; 32(2): 212–217.
  9. Baldo A, Baldo A. Tacrolimus ointment in the management of atopic dermatitis. Clinical, Cosmetic and Investigational Dermatology. 2009: 1.
  10. Paller A, Eichenfield L, Leung D, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology. 2001; 44(1): S47–S57.
  11. Remitz A, Kyllönen H, Granlund H, et al. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. Journal of Allergy and Clinical Immunology. 2001; 107(1): 196–197.
  12. Adherence to topical tacrolimus 0.1% ointment in children with atopic dermatitis. Journal of the American Academy of Dermatology. 2010; 62(3): AB46.
  13. Atopic Dermatitis. Animal Models of Human Inflammatory Skin Diseases. 2013: 351–351.
  14. BOGUNIEWICZ M. Current management of atopic dermatitis and interruption of the atopic march. Journal of Allergy and Clinical Immunology. 2003; 112(6): S140–S150.
  15. Ruzicka T. Atopic Eczema Between Rationality and Irrationality. Archives of Dermatology. 1998; 134(11).
  16. Reitamo S. Tacrolimus: A new topical immunomodulatory therapy for atopic dermatitis. Journal of Allergy and Clinical Immunology. 2001; 107(3): 445–448.
  17. UK pharma contributes £1 billion for new NHS drugs. PharmacoEconomics & Outcomes News. 2016; 749(1): 36–36.
  18. Simpson E, Hanifin J. Atopic dermatitis. Journal of the American Academy of Dermatology. 2005; 53(1): 115–128.
  19. Katayama I, Aihara M, Ohya Y, et al. Japanese guidelines for atopic dermatitis 2017. Allergology International. 2017; 66(2): 230–247.
  20. Lassus A. Clobetasone butyrate and hydrocortisone butyrate in the treatment of eczema: a double-blind comparison. Current Medical Research and Opinion. 2008; 6(3): 165–167.
  21. FK 506. SpringerReference. .

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl